Blocking signaling through the ectodysplasin A2 receptor (EDA2R), a member of the TNF receptor family, protected tumor-bearing mice from developing muscle atrophy associated with cancer cachexia. Upstream and downstream of EDA2R, “we identified two distinct pathways and we demonstrated their involvement in muscle wasting,” Serkan Kir told BioWorld. Kir is a professor at the Koç University Center for Translational Medicine and corresponding author of the paper reporting the findings, which appeared in Nature on May 10, 2023.
Barely a month and a half after its radioconjugate approach landed a potential $1.7 billion deal with Novartis AG, Bicycle Therapeutics plc drew another big radiopharma player to the table, signing a collaboration agreement with Bayer AG to use Bicycle’s peptide technology to discover and develop radiotherapies against cancer targets. Terms are similar to the Novartis deal, with Bayer paying $45 million up front and Bicycle eligible for development and commercial milestones totaling up to $1.7 billion, and underline the growing interest in the radiopharma space.
Researchers from Hibercell Inc. presented preclinical data for the eukaryotic translation initiation factor 2-α kinase 3 (PERK) inhibitor HC-5404, currently in phase I development for the treatment of solid tumors (NCT04834778).
Pyrimidopyridine derivatives acting as GTPase KRAS G12D inhibitors have been reported in a Sunshine Lake Pharma Co. Ltd. patent as potentially useful for the treatment of cancer.
Beijing Tide Pharmaceutical Co. Ltd. has prepared proteolysis-targeting chimera (PROTAC) compounds comprising an ubiquitin ligase binding moiety bound to a protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) targeting moiety through a linker.
Researchers from Kanaph Therapeutics Inc. have reported the discovery and preclinical evaluation of a small-molecule EGFR inhibitor, KNP-501, being developed as an anticancer agent.
Cell cycle dysregulation in cancer cells represents a clinical option for treating cancer, by using cyclin-dependent kinase 4/6 (CDK4/6) inhibitory agents. Further evaluation on this approach was presented by TYK Medicines Inc., where they focused on the pharmacological action of a CDK7 inhibitor TY-2699a for the potential treatment of cancer.
RSS
